ArticleAmerican journal of epidemiology2026
Effect of exogenous testosterone on cardiovascular, cerebrovascular, and thromboembolic adverse events: results of three complementary research designs.
Article in American journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The cardiovascular risks of exogenous testosterone have been a subject of controversy. In this study, our objective was to examine the association between testosterone (versus glaucoma treatments as an active comparator, with no assumed effect) and the new onset of cardiovascular, cerebrovascular and thromboembolic adverse events, in a US commercial insurance database. Data were analyzed by three complementary designs: inverse propensity score weighting (IPSW), calendar time instrumental variable and instrumented difference-in-differences. Results of these analyses suggest that there is no difference between testosterone and glaucoma treatments regarding the risk of the composite primary endpoint of acute myocardial infarction, ischemic stroke and sudden cardiac arrest/ventricular arrhythmia. In contrast, IPSW analysis identified a negative association between testosterone and the secondary endpoint of venous thromboembolism. However, this association was attenuated towards the null in the calendar time instrumental variable and difference-in-differences analysis, which suggests that there might be unmeasured confounding in the IPSW analysis. Because there is no uniquely suitable method that offers a universally optimal solution for evaluating causal relationships between exposures and outcomes from observational data, using multiple state-of-the-art methods to answer the question of interest can help in assessing the robustness of findings to various forms of unmeasured confounding, thereby aiding in causal inference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.